In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marketing Efforts Pay Off As Admedus Ups CardioCel Centers By 50%

Executive Summary

A new deal with an aortic ring manufacturer, a change of chairman, a hike in the number of centers using its cardiovascular bioscaffold and plans to develop an aortic valve repair scaffold have attracted much attention to Admedus in the past six months. The Australian company’s immunotherapies platform is also advancing well, says CEO Lee Rodne.

Advertisement

Related Content

New Future For Admedus Immunotherapies? – Not Yet
How To Restructure: Admedus Opts For A Restart

Topics

Advertisement
UsernamePublicRestriction

Register

IV004488

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel